HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity

Ettenger, 2018, Meeting report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients, Am J Transplant., 18, 564, 10.1111/ajt.14635 Dharnidharka, 2017, Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice, Transpl Int., 31, 198, 10.1111/tri.13079 Hricik, 2015, Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients, J Am Soc Nephrol., 26, 3114, 10.1681/ASN.2014121234 Dugast, 2016, Failure of calcineurin inhibitor (tacrolimus) weaning randomized trial in long-term stable kidney transplant recipients, Am J Transplant., 16, 3255, 10.1111/ajt.13946 Gatault, 2017, Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study, Am J Transplant., 17, 1370, 10.1111/ajt.14109 Tambur, 2018, Sensitization in Transplantation: Assessment of Risk (STAR) 2017 working group meeting report, Am J Transplant., 15, 462 2009, Special issue: KDIGO clinical practice guideline for the care of kidney transplant recipients, Am J Transplant., 9, S1 Tait, 2013, Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation, Transplantation., 95, 19, 10.1097/TP.0b013e31827a19cc Wiebe, 2017, Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development, Am Soc Nephrol., 28, 3353, 10.1681/ASN.2017030287 Wiebe, 2013, Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes, Am J Transplant., 13, 3114, 10.1111/ajt.12478 Wiebe, 2015, Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody, Am J Transplant., 15, 2921, 10.1111/ajt.13347 Duquesnoy, 2007, HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ and HLA-DP, Hum Immunol., 68, 12, 10.1016/j.humimm.2006.10.003 Stegall, 2016, Developing new immunosuppression for the next generation of transplant recipients: the path forward, Am J Transplant., 16, 1094, 10.1111/ajt.13582 OʼConnell, 2017, Clinical trials for immunosuppression in transplantation: the case for reform and change in direction, Transplantation., 101, 1527, 10.1097/TP.0000000000001648 Neuberger, 2017, Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group, Transplantation., 101, S1, 10.1097/TP.0000000000001651 Djamali, 2014, Diagnosis and management of antibody-mediated rejection: current status and novel approaches, Am J Transplant., 14, 255, 10.1111/ajt.12589 Wiebe, 2012, Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant, Am J Transplant., 12, 1157, 10.1111/j.1600-6143.2012.04013.x Bray, 2006, Transplanting the highly sensitized patient: the emory algorithm, Am J Transplant., 6, 2307, 10.1111/j.1600-6143.2006.01521.x Wehmeier, 2017, Donor specificity but not broadness of sensitization is associated with antibody-mediated rejection and graft loss in renal allograft recipients, Am J Transplant., 17, 2092, 10.1111/ajt.14247 Williams, 2016, The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors, Transplantation., 100, 1094, 10.1097/TP.0000000000001115 Wiebe, 2018, Carpe diem-time to transition from empiric to precision medicine in kidney transplantation, Am J Transplant., 18, 1615, 10.1111/ajt.14746 Mannon, 2018, Meeting report of the STAR-Sensitization in Transplantation Assessment of Risk: naïve abdominal transplant organ subgroup focus on kidney transplantation, Am J Transplant., 18, 1604 Harrison, 1956, Renal homotransplantation in identical twins, Surg Forum., 6, 432 Kosmoliaptsis, 2011, High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes, Hum Immunol., 72, 1049, 10.1016/j.humimm.2011.07.303 Wiebe, 2018, A comparison of HLA molecular mismatch methods to determine HLA immunogenicity, Transplantation., 102, 1338, 10.1097/TP.0000000000002117 Kosmoliaptsis, 2016, Alloantibody responses after renal transplant failure can be better predicted by donor-recipient HLA amino acid sequence and physicochemical disparities than conventional HLA matching, Am J Transplant., 16, 2139, 10.1111/ajt.13707 2016 Wiebe, 2015, The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival, Am J Transplant., 15, 2197, 10.1111/ajt.13341 Sapir-Pichhadze, 2015, HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study, Am J Transplant., 15, 137, 10.1111/ajt.12968 Freidlin, 2014, Biomarker enrichment strategies: matching trial design to biomarker credentials, Nat Rev Clin Oncol., 11, 81, 10.1038/nrclinonc.2013.218